A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection (VATH-1)
Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor
About this trial
This is an interventional treatment trial for Vonoprazan focused on measuring vonoprazan, Helicobacter Pylori, Proton pump inhibitor
Eligibility Criteria
Patients aged ≥18 years with Hp-positive first sterilization were included in this study. Before treatment, the existence of Helicobacter pylori can be confirmed by one or more of the following methods: rapid urease test, Hp culture, 13C urea breath test, 14C urea breath test and stool Hp antigen test.
The main exclusion criteria include acute upper gastrointestinal bleeding, active gastric or duodenal ulcer, acute gastric or duodenal mucosal lesions, previous eradication treatment of Helicobacter pylori, penicillin/furazolidone allergy, surgery that may affect gastric acid secretion (upper gastrointestinal resection or vagotomy), Zollinger-Ellison syndrome or other hypergastric acid secretion diseases, severe neurological, cardiovascular, pulmonary, liver, renal, metabolic, gastrointestinal, urological, etc. Any fertile woman must use proper contraception. All subjects provided written informed consent before participating in the study.
Sites / Locations
- Hangzhou first people's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
vonoprazan 20mg QD
esomeprazole 20 mg BID
Vonoprazan 20 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg,clarithromycin 500mg bid,colloidal bismuth pectin 200mg bid for up to 2 weeks. OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks.